Nature: IgM neutralizing antibody is administered nasally to provide a wide range of protection against new crown variants

On June 3, 2021, Nature published a collaboration between Chinese scientists An Zhiqiang and Zhang Ningyan from the University of Texas Health Science Center, Shi Peiyong from the Medical Office of the University of Texas, and Stephen F.

In this communication, as the following four scientists, the first three are all Chinese scientists from the University of Texas, and the last one is the vice president of preclinical research and development of IgM Biosciences.

From left to right: Zhang Ningyan, An Zhiqiang, Shi Peiyong, Stephen F.

Compared with IgG, CoV-14 neutralizing antibody of IgM subtype has significantly enhanced affinity, neutralizing activity, and ACE2 blocking effect.

The neutralizing antibody of IgM maintains a high degree of neutralizing activity against a variety of mutants.

In vivo experiments have shown that the nasal administration of neutralizing antibodies of IgM subtypes, whether for prevention or treatment, provides a wide range of protective effects.

In April 2020, BeiGene, Atreca, and IgM Bioscience reached a cooperation to jointly develop neutralizing antibodies for the new crown IgM or IgA subtypes.

Original source:

Ku, Z.